Slide 1: Bora Pharmaceuticals Investor Conference
Bora Pharmaceuticals Investor Conference Nov. 18th .2021 股票代號：6472
Slide 2: Table of Contents
Company Introduction Company fact sheet, leadership team, milestones 01 Operation Highlights 02 CDMO operation: facilities, CDMO services Commercial operation 03 Financial Results Finansial results, successful M&A model Table of Contents 04 Bora’s Growth Strategy Investor Conference 05 Future Outloo
Slide 3: Bora by the numbers
500 Million USD Market Cap 800+ Employees Bora by the 3 Manufacturing Sites 100+ Export Countries numbers 1.2B+ Annual Units Produced 98% On-Time Delivery 3 Completed M&A in 5 years
Slide 4: Bora's Companies Portfolio
Bora’s Companies Portfolio 保瑞集團 Bora Group Bora Pharmaceuticals Bora Pharmaceutical Bora Pharmaceuticals Bora Pharmaceutical 聯邦化學製藥股份 保瑞聯邦股份 (Tainan Facility) Laboratories(Zhunan) USA (USA) Services (Canada) 有限公司 有限公司 Global CDMO Operations Commercial Operations
Slide 5: Global Leadership Team
國際專業領導團隊 Global Leadership Team
Slide 6: Operational Highlight
Operational Highlight
Slide 7: Mississauga Site
Mississauga Site From cost center to profit center April. 2021 Complete Health KPI 2021 Canada Inspection GSK Products June. 2021 Profit Global leading CDMO partner Complete System Center Cutover from GSK New Business Development
Slide 8: Main Product Zhunan Facility
Zhunan Facility KCl /CONST-K Performance Rytary/Numient KCl won bid into Numient received drug Main Product Main Product retailer Walgreens. pricing approval by Taiwan 進入美國大型連鎖通路Walgreens， National Health Insurance 為美國處方數排名第37之藥品。 2021 取得台灣健保藥價給付 Const-K received drug pricing Exclusive Rights to app
Slide 9: Numient Market
Numient Market瑞多寧亞洲市場 Exclusive Rights to Commercialize Numient in 11 countries in Asia 取得瑞多寧於中港澳、日、韓、泰等亞洲多國經銷權 The predicted increased prevalence of PD in individuals over 50 years old1 By 2030, the global prevalence of PD is expected to more than Number of individuals with PD (millions) 5 double,
Slide 10: New CDMO Projects
New CDMO Projects 2 505 (b)(2) &1NCE Products New Contracts Signed in Bora Mississauga since Day One New Contracts Signed in Bora Zhunan 2 505 (b)(2) &1NCE Products
Slide 11: Commercial Operation
Commercial Operation
Slide 12: Chocola BB
Chocola , BB ChocolaBB aS 2 PR HR SS HE Lc - \ BETA RHE / BARE Rohe BOOST x ie BOolReN Ba Dobe te we smanne fs oscillococcinum ql D a —;
Slide 13: Complete Distribution Channel Coverage
Complete Distribution Channel Coverage 多元通路持續拓展 Distribution Channel Increase BB Chocola into Costco Q4 進駐全台好市多 Hospitals • Medical Center • Regional Hospital • Foundation Hospital Clinics • General Physician • Area Distributor Pharmacies • BNHI Pharma • CVS • Chain Store
Slide 14: In-Licensing Performance
In-Licensing Performance KCL/CONST-K Rytary/Numient Indication: Hypokalemia Indication: Parkinson Disease Numient received drug pricing approval by Const-K received drug pricing approval by Taiwan National Health Insurance Taiwan National Health Insurance 取得台灣健保藥價給付 2021 取得台灣健保藥價給付 In TFDA essential
Slide 15: Financial Results
Contributing to Better Health All
Slide 16: Consolidated Financial Statement
Consolidated Financial Statement $NTD Million 2020 2019 2020 2021 Q3 Year Variation Amount % Amount % % Amount Revenue !"#$% !&&' !"(&& !&&' )!(' *"+#& Gross Profit ,-* -#039; +&- *%' )%' !"$%+ Operating Expense $%( amp;' -+( $,' ),&' -*+ Net Operating Income *-- $' $, !*' .*-' (,& Non-operating Income
Slide 17: Revenue
Revenue Units: NTD 100 Million 6 $5.44 5 $4.48 $4.41 $4.27 $4.25 4 $4.14 $4.04 $3.95 $3.66 $3.38 3 2 1.33 1.46 1.21 1.24 1.3 1.32 1.18 1.08 1.18 1 0 Jan Feb Mar Apr May Jun Jul Aug Sep 2020 2021 Excluded One Time
Slide 18: Financial Performance
Financial Performance 4000 3500 3750 3000 2500 Revenue 2000 1500 1372 1529 1800 1000 Gross Profit 358 500 1297 126 19 445 445 643 704 15 187 344 0 305 578 860 226 Net Operating Income 2017 610 2018 2019 Net Profit 2020 2021 Q3
Slide 19: Balance Sheet
資產負債表摘要 BALANCE SHEET 3Q21 2Q21 3Q20 (新台幣百萬 $NTD Million) 金額Amount % 金額Amount % 金額Amount % 現金及約當現金 Cash and cash equivalents 1,482 19% 1,176 15% 783 21% 應收帳款 Accounts receivable 792 10% 893 11% 273 7% 存貨 Inventories 994 13% 981 13% 306 8% 不動產、廠房及設備 Property, plant, and equipment 3,760 48% 3,793 49%
Slide 20: Financial Performance
Financial Performance 7 6 Bora Dividends 6 5 5 4.5 4 3 2 1 0.8 1 0.5 0 2016 2017 2018 2019 2020 2021 2021 Payout A POWERFUL VALUE-CREATING Cash Dividends NT$ 2 BUSINESS MODEL Stock Dividends NT$ 2.46
Slide 21: Bora's Growth Strategy
Bora’s Growth Strategy
Slide 22: CDMO Market
CDMO MARKET $130.8 $278.98 BILLION BILLION 2018 2026 CAGR 10.0% 2019-2026 Source: https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502
Slide 23: Annual Revenue Growth
Annual Revenue Growth Inorganic Growth Unit: NT$ 100M 50 Organic Growth 37.5 45 40 Inorganic 35 Growth 30 25 17.9 Organic Growth 15.29 20 13.72 15 10 6.84 2.83 3.58 5.41 2.18 2.38 3.94 5 2.24 2.24 2.33 2.64 2.94 0 2014 2015 2016 2017 2018 2019 2020 2021 Q3 Share Capital Revenue
Slide 24: Bora Market Cap
Bora Market Cap 16 14.8 14 12 10.63 10 8 5.91 Market Cap 6 multiplied by 12x 4 3.18 since IPO! 2 1.2 0 2013 2014 2017 2018 2019 2020 2021 Q3
Slide 25: Bora's Industry Integration Plan
Bora’s Industry Integration Plan Current Capabilities Future growth targets
Slide 26: Bora's Two-Pronged Growth Strategy
Bora’s Two-Pronged Growth Strategy Organic Growth • High Focus on new business with continued investment Marketing and Sales. • Build strong pipeline of development project. • Invest in new technologies to increase commercial scale efficiency. • Invest in new production lines and formulations to inc
Slide 27: Future Outlook
bell Contributing to Better Health All bora Over the World
Slide 28: Future Outlook
CDMO 國際委託研發暨生產服務 • Voltaren, Flonase, Rytary, and KCL continue to grow 未來展望2022 產品訂單持續成長 • Continue to increase customers Future Outlook 北美業務開發團隊積極拓展 • Expanding cooperation with big pharma 專注增加大型生技製藥客戶 • Continue to find M&A opportunities 持續評估併購標的 • Invest in R&D and product development 投入新產品線及研發 •
Slide 29: Bora's Dedication to Become Global
Bora’s Dedication to Become Global Capture Global Markets • Strategic M&A within US, EU, and Continuous Expansion Asia • Launch New • Increase International Products and CDMO partners Dosage Form Stable Profitability • Pharmaceutical • Expand Pharma CDMO and CHC products • Pharmaceutical/ Health Pro
Slide 30: Contributing to Better Health All Over the World
Contributing to Better Health All Over the World